🔗 Share this article

While the US undertakes historic changes to its immunization schedules, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by casting doubt on COVID-19 vaccines in the pandemic and has zeroed in on alleged fatalities following COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Vaccine Schedule

Agency leaders had intended to unveil radical changes to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s national calendar, according to reports – a significant shift that would put the US out of alignment with much of the international standard with no evidence for improved outcomes. The planned update has been postponed until the new year.

In place of Vinay Prasad, Dr. Høeg is listed to address the audience at the event. She was recently named interim head of the FDA’s CDER, the fifth person to head the office this calendar year.

Consolidating Power at the Regulatory Body

This interim role could signify a tighter collaboration between the drug and vaccine branches as Høeg and Prasad consolidate power at the agency – and it suggests a renewed priority upon rolling back previously authorized vaccines at the FDA.

The new acting director has frequently advocated for discontinuing certain childhood vaccine recommendations in the US to become more in line with the Danish model, a country with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccines – usually the domain of Prasad, director of the FDA’s CBER – instead of drug regulation.

Questions Over Qualifications

Dr. Høeg has no apparent track record in drug development, oversight or management, which has been standard for former leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the agency head and CBER since spring.

“She doesn’t seem to have the requisite experience” for running the drug-regulation department, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in managing a major agency. She is not an expert in pharmaceutical oversight.”

Former commissioners of CBER would “understand regulatory frameworks and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that former directors who led the center have had.”

This division has an enormous range of responsibilities at the FDA, Woodcock stated.

“The public just focuses on the innovative therapies, but the generic drug division approves thousands of off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and other areas, and each of these have to be managed,” she noted. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major management component to the role, which supervises in excess of 5,000 staff members. “It’s a huge leadership role, if you do it right,” the former official concluded.

Agency Reaction and Contentious Policies

Regarding questions about Dr. Høeg's credentials and whether this assignment signifies more teamwork among regulatory chiefs on immunizations, a spokesperson stated that the “concerns are based on flawed presumptions”.

“Her experience matches the duties of her position,” the official said, citing the time Høeg spent guiding the agency head on “drug safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a contentious rapid drug-approval program that reportedly concerned her predecessors. “How are these medications being chosen for this voucher program? Who makes the choices?” Howard said. “There is a lot of secrecy occurring at the FDA right now.”

Overall, he remarked, “the agency seems to be moving towards more relaxed rules of most medications, aside from immunizations.”

Established History on Immunizations

Concerning vaccines, Høeg has a more documented, if concerning, history, Howard have noted. She released a research paper using unconfirmed crowd-sourced reports to assess the rate of heart inflammation after Covid vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccines are more dangerous than they are.

Included in her “policy goals” for the incoming federal leadership included revising regulations for novel immunizations and discontinuing “optional” vaccines, she said after the election on a podcast. At the FDA, Høeg has allegedly proposed excluding teenage boys from receiving Covid vaccines.

“She is an all-around true believer who starts off with her beliefs and tailors the evidence to retrofit the evidence in a very misleading, dishonest manner,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg joined fellow dissenters, {like|